Ixazomib
- Generic Name
- Ixazomib
- Brand Names
- Ninlaro
- Drug Type
- Small Molecule
- Chemical Formula
- C14H19BCl2N2O4
- CAS Number
- 1072833-77-2
- Unique Ingredient Identifier
- 71050168A2
- Background
Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortezomib (the first PI approved for multiple...
- Indication
Ixazomib is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
- Associated Conditions
- Multiple Myeloma (MM)
- Associated Therapies
- -
A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)
- Conditions
- Interventions
- First Posted Date
- 2017-06-01
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Takeda
- Target Recruit Count
- 141
- Registration Number
- NCT03173092
- Locations
- 🇺🇸
Saint Agnes Hospital, Baltimore, Maryland, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Pacific Cancer Medical Center, Anaheim, California, United States
A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2017-05-31
- Last Posted Date
- 2022-12-20
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 122
- Registration Number
- NCT03170882
- Locations
- 🇮🇹
Centro Di Riferimento Oncologico, Aviano, Italy
🇮🇹Azienda Ospedaliero Universitaria Di Bologna - Policlinico S Orsola Malpighi, Bologna, Emilia-Romagna, Italy
🇨🇦Lakeridge Health Center, Ottawa, Ontario, Canada
NINLARO Capsules Drug Use-Results Survey (All-Case Surveillance) "Relapsed/Refractory Multiple Myeloma"
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2023-12-07
- Lead Sponsor
- Takeda
- Target Recruit Count
- 774
- Registration Number
- NCT03169361
- Locations
- 🇯🇵
Takeda Selected Site, Tokyo, Japan
Study of Ixazomib to Prevent Recurrent or Late Acute and Chronic Graft-versus-Host Disease 1-year After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2017-03-17
- Last Posted Date
- 2022-09-27
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT03082677
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-12-15
- Last Posted Date
- 2020-11-30
- Lead Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Target Recruit Count
- 31
- Registration Number
- NCT02993094
- Locations
- 🇦🇹
Klinikum Kreuzschwestern Wels GmbH, Wels, Oberösterreich, Austria
🇦🇹Landeskrankenhaus Feldkirch, Innere Med. II, Interne E, Feldkirch, Vorarlberg, Austria
🇦🇹KUK Linz: Klinik für Interne 3 - Schwerpunkt Hämatologie und Onkologie, Linz, Austria
Study of Ixazomib and Erlotinib in Solid Tumors
- First Posted Date
- 2016-10-21
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 9
- Registration Number
- NCT02942095
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Ixazomib Rollover Study
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Takeda
- Target Recruit Count
- 31
- Registration Number
- NCT02924272
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇨🇦University Health Network, Toronto, Ontario, Canada
🇨🇦Princess Margaret Cancer Centre, Toronto, Ontario, Canada
A Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Participants With Relapsed and/or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2016-09-28
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- Takeda
- Target Recruit Count
- 34
- Registration Number
- NCT02917941
Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2016-09-27
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 55
- Registration Number
- NCT02916771
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2016-09-13
- Last Posted Date
- 2022-09-26
- Lead Sponsor
- Brian Hill
- Target Recruit Count
- 19
- Registration Number
- NCT02898259
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸University Hospitals, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.